Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeoImmuneTech, Inc.

http://neoimmunetech.com/

Latest From NeoImmuneTech, Inc.

Kriya Raises $270m To Scale Gene Therapy Platform, Move Into The Clinic

The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023. 

Financing Gene Therapy

Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk

Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.

Coronavirus COVID-19 Companies

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

Cellid IPO To Fund First-In-Class Cancer Immunotherapeutic Vaccines

After using government financial support to fund its early-stage clinical trials, Korean bioventure Cellid aims to further progress its first-in-class, cell-based cancer immunotherapeutic vaccines through an initial public offering in February.

South Korea Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
UsernamePublicRestriction

Register